News
Public · Published
Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
Moderna announced that JAMA Network Open published a real-world comparison of mNEXSPIKE and Comirnaty in 294,499 matched U.S. veterans aged 65 and older during the 2025–2026 respiratory virus season. mNEXSPIKE was associated with 35.9% lower risk of medically attended COVID-19 and 47.0% lower risk of COVID-19-associated hospitalization.
Published:
Updated:
What happened
Moderna announced that JAMA Network Open published a real-world comparison of mNEXSPIKE and Comirnaty in 294,499 matched U.S. veterans aged 65 and older during the 2025–2026 respiratory virus season. mNEXSPIKE was associated with 35.9% lower risk of medically attended COVID-19 and 47.0% lower risk of COVID-19-associated hospitalization.
Confirmed
Global impact / market context
The results may support demand for Moderna’s vaccine among older adults if clinicians, health systems, or patients respond to the reported differences. Greater use could raise vaccine revenue, while the study’s veteran population and observational design limit how confidently the findings apply to broader groups.
Analyst inference
The comparison is between two COVID-19 vaccines, not between vaccination and no vaccination, so it does not establish the size of the overall vaccine market. The reported effectiveness is an association, and the article supplies no sales, pricing, or market-reaction data.
Analyst inference
What to watch
- Watch for further study details on how participants were matched and how outcomes were measured; these could clarify whether the reported differences translate to other older-adult populations. Analyst inference
- Look for uptake or sales information for mNEXSPIKE in older adults; stronger demand could increase Moderna’s vaccine revenue, while weak adoption would limit that commercial benefit. Analyst inference
- The article reports results from 294,499 matched U.S. veterans aged 65 and older in the 2025–2026 season, with lower associated risks for both outcomes. Confirmed